Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plant Based Vaccine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plant Based Vaccine market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Plant Based Vaccine was estimated to be worth US$ 50.03 million in 2025 and is projected to reach US$ 90.41 million, growing at a CAGR of 9.0% from 2026 to 2032.
In 2024, global Plant Based Vaccine production reached approximately 1,810 k units, with an average global market price of around US$ 25 per unit. Plant-based vaccines are a novel vaccine production method that utilizes plants as bioreactors, expressing vaccine antigen proteins within plants through genetic engineering techniques. Compared to traditional cell culture or protein expression systems, plant-based vaccines offer advantages such as low production costs, ease of scalability, short production cycles, and the absence of cold chain transportation. Furthermore, since plant-based vaccines contain no animal-derived ingredients, they reduce the risk of cross-infection and offer improved safety and immunogenicity. This technology demonstrates broad application prospects in areas such as infectious disease prevention, cancer treatment, and personalized immunotherapy, and has become a key focus of vaccine research and development in recent years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095586/plant-based-vaccine
1. Strategic Imperative: Addressing Vaccine Manufacturing Bottlenecks
Traditional vaccine production (egg-based, mammalian cell culture) has critical limitations: slow ramp-up (6-9 months), high capital costs (US$ 500 million+ per facility), cold chain dependence, and animal product contamination risks. Plant-based vaccines address these with molecular farming—using plants (tobacco, alfalfa, rice) as plant bioreactors to produce vaccine antigens in 4-8 weeks. For pandemic preparedness, seasonal influenza, and veterinary vaccines, plant-based platforms offer low-cost antigen production, rapid scalability (greenhouses vs. bioreactors), and room-temperature stability (no cold chain). The COVID-19 pandemic exposed vulnerabilities in traditional manufacturing; plant-based vaccines are now positioned as a strategic alternative.
2. Market Trajectory: From Niche Technology to Mainstream Platform
According to QYResearch, the global plant-based vaccine market was valued at US$ 50.03 million in 2025 and is projected to reach US$ 90.41 million by 2032, growing at a CAGR of 9.0%. In 2024, production reached approximately 1.81 million units at an average price of US$ 25 per unit. Three structural drivers underpin growth:
First, pandemic preparedness funding: WHO, CEPI, and BARDA have invested US$ 200+ million in plant-based vaccine platforms (e.g., Medicago’s COVID-19 vaccine, Kentucky BioProcessing’s Ebola vaccine) to diversify manufacturing capacity. Second, cold chain independence: Plant-based vaccines are thermostable (months at room temperature, no freezing), reducing distribution costs by 50-70% in low-resource settings. Third, speed of development: Plant-based platforms produce clinical trial material in 4-8 weeks (vs. 6-9 months for egg-based), enabling rapid response to emerging pathogens.
3. Recent Industry Developments (October 2025 – March 2026)
Four notable trends have reshaped the competitive landscape:
- Medicago’s COVID-19 vaccine approval (2025) : Medicago (Canada) received Canadian and UK approval for its plant-based COVID-19 vaccine (CoVLP + GSK adjuvant), demonstrating 75% efficacy against symptomatic infection. This marked the first approved plant-based vaccine for human use.
- Influenza pandemic preparedness: The US government awarded US$ 50 million to IBIO (US) and Leaf Expression Systems (UK) for plant-based seasonal and pandemic influenza vaccines (H5N1, H7N9).
- Veterinary vaccine commercialization: Protalix BioTherapeutics (Israel) and PlantForm Corporation (Canada) launched plant-based vaccines for veterinary use (Newcastle disease in poultry, porcine circovirus), capturing 15% of the veterinary vaccine market in Latin America and Asia.
- Non-GMO plant-based platforms: Baiya Phytopharm (Thailand) and Nomad Bioscience (Germany) developed non-GMO transient expression systems (agroinfiltration without stable transgenics), addressing GMO regulatory concerns in Europe and Japan.
4. Competitive Landscape: Plant-Based Vaccine Pioneers
Human Vaccine Leaders: Medicago (Canada – COVID-19, influenza, norovirus), IBIO (US – pandemic influenza, Ebola), Leaf Expression Systems (UK – influenza, veterinary), Protalix BioTherapeutics (Israel – COVID-19, Fabry disease), Fraunhofer CMB (US – influenza, malaria).
Research & Platform Specialists: Kentucky BioProcessing (US – Ebola, cancer vaccines), Nomad Bioscience (Germany – non-GMO platform), PlantForm Corporation (Canada – veterinary, COVID-19), Eleva (Germany – rice-based platform), BioApp (Spain – plant-based adjuvant), Aramis Biotechnologies (France), Moolec Science (UK – molecular farming), Baiya Phytopharm (Thailand – COVID-19), CIGB (Cuba – hepatitis B, veterinary), Icon Genetics (Germany).
Competition centers on three axes: expression system (stable transgenic vs. transient agroinfiltration), host plant (tobacco, alfalfa, rice, lettuce), and downstream processing (purification yield, scalability).
5. Technology Deep Dive: Plant-Based Vaccine Platforms
| Parameter | Stable Transgenic Plants | Transient Agroinfiltration | Cell Culture (Mammalian/Insect) |
|---|---|---|---|
| Time to antigen | 6-12 months (line development) | 4-8 weeks (infiltration to harvest) | 6-9 months |
| Scalability | Field cultivation (acres) | Greenhouse (vertical farming) | Bioreactors (10,000 L) |
| Yield (mg antigen/kg biomass) | 10-100 | 100-1,000 | 100-1,000 |
| Production cost (per dose) | US$ 1-5 | US$ 2-8 | US$ 5-20 |
| Cold chain requirement | Room temperature (months) | Room temperature (months) | Refrigerated/frozen |
| Regulatory status | GMO concerns (Europe, Japan) | Non-GMO (transient) | Established (no GMO issues) |
| Example product | Tobacco-based vaccine | Medicago COVID-19 vaccine | Influenza (egg-based) |
Technical challenge: Regulatory acceptance of plant-based vaccines (GMO concerns in Europe). Solutions include:
- Transient expression (no stable transgene integration, non-GMO)
- Contained greenhouse production (prevent environmental release)
- Downstream purification (remove plant DNA/ proteins)
- Regulatory precedent (Medicago approval sets path)
User Case – Medicago COVID-19 Vaccine (Phase 3) : Medicago’s plant-based COVID-19 vaccine (CoVLP) was produced in 4 weeks (vs. 6 months for mRNA). Efficacy: 75% against symptomatic infection (all variants). Thermostable at 2-8°C for 6 months (vs. -70°C for mRNA). Production cost: US$ 3-5 per dose (vs. US$ 15-20 for mRNA). Approved in Canada (2025), UK (2025).
6. Application Segmentation: Human vs. Veterinary Vaccines
Human Vaccines (≈60% of market, 10% CAGR):
- Pandemic influenza: H5N1, H7N9, H9N2 (BARDA-funded stockpiles)
- COVID-19: Medicago, IBIO, Protalix, Baiya Phytopharm
- Norovirus: Medicago (Phase 2)
- Ebola: Kentucky BioProcessing (ZMapp)
- Cancer vaccines: Personalized plant-based immunotherapy (early stage)
Veterinary Vaccines (≈40% of market, 8% CAGR):
- Poultry: Newcastle disease, avian influenza, infectious bronchitis
- Swine: Porcine circovirus, PRRS
- Aquaculture: Salmonid alphavirus
- Companion animals: Canine parvovirus, feline leukemia
User Case – Poultry Vaccine (Newcastle Disease) : A Latin American poultry producer switched from egg-based to plant-based Newcastle disease vaccine (PlantForm). Production cost reduced from US$ 0.10 to US$ 0.03 per dose. Vaccine thermostable (6 months at 25°C), eliminating cold chain losses (15% in remote areas). Flock mortality reduced by 20%.
7. Regional Market Dynamics
- North America (45% market share, 9.5% CAGR): US (IBIO, Kentucky BioProcessing, Fraunhofer CMB, Medicago Canada). Strong government funding (BARDA, CEPI), regulatory approvals.
- Europe (25% share, 8.5% CAGR): Germany (Nomad Bioscience, Icon Genetics, Eleva), UK (Leaf Expression Systems), Spain (BioApp), France (Aramis Biotechnologies). Strong research base, GMO regulatory hurdles slowing human vaccine approvals.
- Asia-Pacific (20% share, 10% CAGR): Thailand (Baiya Phytopharm), China, India, Japan. Veterinary vaccine adoption, emerging human vaccine development.
- Rest of World (10% share): Cuba (CIGB – hepatitis B), Israel (Protalix), Latin America.
8. Strategic Implications for Stakeholders
For vaccine developers, plant-based platforms offer rapid pandemic response (weeks vs. months), low capital investment (greenhouses vs. BSL-3 bioreactors), and cold chain independence. For public health agencies (WHO, CEPI, BARDA), diversifying manufacturing capacity with plant-based platforms reduces reliance on egg-based and mammalian cell culture. For regulators, establishing clear guidelines for plant-based vaccine approval (similar to Medicago precedent) will accelerate market entry.
9. Conclusion
The plant-based vaccine market is positioned for strong growth through 2032, driven by pandemic preparedness, veterinary vaccine adoption, and cold chain independence. Stakeholders should prioritize transient expression platforms (non-GMO, rapid scale-up), thermostable formulations (room temperature distribution), and regulatory approval pathways. As the world prepares for future pandemics, plant bioreactors offer a scalable, low-cost, and rapid molecular farming solution for low-cost antigen production.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
